{"verbs": [{"verb": "solo-1", "description": "[V: solo-1] [ARG1: phase iii trial] demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["B-V", "B-ARG1", "I-ARG1", "I-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "demonstrates", "description": "[ARG0: solo-1 phase iii trial] [V: demonstrates] [ARG1: lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer]", "tags": ["B-ARG0", "I-ARG0", "I-ARG0", "I-ARG0", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1"]}, {"verb": "cut", "description": "solo-1 phase iii trial demonstrates [ARG0: lynparza maintenance therapy] [V: cut] [ARG1: the risk of disease progression or death] [ARG2: by 70] [ARGM-LOC: in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage] stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "B-ARG0", "I-ARG0", "I-ARG0", "B-V", "B-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "I-ARG1", "B-ARG2", "I-ARG2", "B-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "I-ARGM-LOC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "diagnosed", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with [ARGM-TMP: newly] - [V: diagnosed] advanced [ARG2: brca] - mutated [ARG1: ovarian cancer] wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARGM-TMP", "O", "B-V", "O", "B-ARG2", "O", "O", "B-ARG1", "I-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "mutated", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced [ARG2: brca] - [V: mutated] [ARG1: ovarian cancer] wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG2", "O", "B-V", "B-ARG1", "I-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "inc", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck [ARG2: co] [V: inc] kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ARG2", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "meixell", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele [V: meixell] kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "inc", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co [V: inc] oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "brca1", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall [V: brca1] [ARG1: stomatitis] congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "B-ARG1", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "kathleen", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany [V: kathleen] moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city her2-negative breast cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O"]}, {"verb": "her2-negative", "description": "solo-1 phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by 70 in patients with newly - diagnosed advanced brca - mutated ovarian cancer wilmington del business wire -oct 21 2018-astrazeneca and merck co inc kenilworth n j merck metastatic breast cancer dna damage stephenson cancer center executive vice president global medicines development and chief medical officer cancer ovarian cancer abdominal pain primary peritoneal cancer oncology seville united states fever acerta pharma merck strategic oncology collaboration 70 new england journal of medicine michele meixell kenilworth dyspnea canada merck co inc oklahoma disease senior vice president and head of global clinical development lynparza her2 negative breast cancer bevacizumab chief medical officer mechanism of action merck research laboratories metabolism primary peritoneal carcinoma stephanie wiswall brca1 stomatitis congress del respiratory tract sean bohen munich brca associate director for clinical research co - principal investigator germany kathleen moore roy baynes america nausea leukopenia european society for medical oncology arthralgia wilmington myalgia astrazeneca health biotechnology clinical trials oncology pharmaceutical n j pancreatic cancers oklahoma city [V: her2-negative] [ARG1: breast] cancer", "tags": ["O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-V", "B-ARG1", "O"]}], "words": ["solo-1", "phase", "iii", "trial", "demonstrates", "lynparza", "maintenance", "therapy", "cut", "the", "risk", "of", "disease", "progression", "or", "death", "by", "70", "in", "patients", "with", "newly", "-", "diagnosed", "advanced", "brca", "-", "mutated", "ovarian", "cancer", "wilmington", "del", "business", "wire", "-oct", "21", "2018-astrazeneca", "and", "merck", "co", "inc", "kenilworth", "n", "j", "merck", "metastatic", "breast", "cancer", "dna", "damage", "stephenson", "cancer", "center", "executive", "vice", "president", "global", "medicines", "development", "and", "chief", "medical", "officer", "cancer", "ovarian", "cancer", "abdominal", "pain", "primary", "peritoneal", "cancer", "oncology", "seville", "united", "states", "fever", "acerta", "pharma", "merck", "strategic", "oncology", "collaboration", "70", "new", "england", "journal", "of", "medicine", "michele", "meixell", "kenilworth", "dyspnea", "canada", "merck", "co", "inc", "oklahoma", "disease", "senior", "vice", "president", "and", "head", "of", "global", "clinical", "development", "lynparza", "her2", "negative", "breast", "cancer", "bevacizumab", "chief", "medical", "officer", "mechanism", "of", "action", "merck", "research", "laboratories", "metabolism", "primary", "peritoneal", "carcinoma", "stephanie", "wiswall", "brca1", "stomatitis", "congress", "del", "respiratory", "tract", "sean", "bohen", "munich", "brca", "associate", "director", "for", "clinical", "research", "co", "-", "principal", "investigator", "germany", "kathleen", "moore", "roy", "baynes", "america", "nausea", "leukopenia", "european", "society", "for", "medical", "oncology", "arthralgia", "wilmington", "myalgia", "astrazeneca", "health", "biotechnology", "clinical", "trials", "oncology", "pharmaceutical", "n", "j", "pancreatic", "cancers", "oklahoma", "city", "her2-negative", "breast", "cancer"]}